The New England journal of medicine, 2021-03, Vol.384 (11), p.989-1002
2021
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- Ist Teil von
- The New England journal of medicine, 2021-03, Vol.384 (11), p.989-1002
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2021
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- This double-blind study randomly assigned adults with obesity (or overweight and with one or more weight-related coexisting conditions) without diabetes to 68 weeks of once-weekly subcutaneous semaglutide (2.4 mg) or placebo, plus lifestyle intervention. Semaglutide therapy was associated with sustained, clinically relevant weight reduction.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2032183Titel-ID: cdi_proquest_journals_2502230375
- Format
- –
- Schlagworte
- Adult, Adverse events, Anti-Obesity Agents - administration & dosage, Anti-Obesity Agents - adverse effects, Antidiabetics, Body composition, Body Composition - drug effects, Body Mass Index, Body weight, Body weight loss, Cardiovascular disease, Cholelithiasis - chemically induced, Clinical trials, Coronaviruses, COVID-19, Diabetes, Diabetes mellitus, Diarrhea, Diarrhea - chemically induced, Diet, Dosage, Double-Blind Method, Female, Gastrointestinal surgery, Glucagon-Like Peptide 1 - agonists, Glucagon-Like Peptides - administration & dosage, Glucagon-Like Peptides - adverse effects, Healthy Lifestyle, Humans, Hypertension, Injections, Subcutaneous, Intervention, Lifestyles, Lipids - blood, Male, Middle Aged, Nausea, Nausea - chemically induced, Obesity, Obesity - complications, Obesity - drug therapy, Overweight, Pancreatitis, Placebos, Prediabetic State - complications, Public health, Risk factors, Weight control, Weight Loss - drug effects